A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Trial Profile

A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB-IVB) mycosis fungoides (MF) or Sezary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Oct 2017

At a glance

  • Drugs Resminostat (Primary)
  • Indications Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms RESMAIN
  • Sponsors 4SC
  • Most Recent Events

    • 31 Aug 2017 According to a 4SC media release, data from this study will be presented at the EORTC CLTF Meeting, Cutaneous Lymphomas: Insights & Therapeutic Progress 2017 Meeting.
    • 03 May 2017 According to a 4SC media release, this study was presented at the 13th Congress of the European Association of Dermato-Oncology.
    • 16 Dec 2016 According to a 4SC media release, first patient has been enrolled. Company anticipates top-line data of this trial to be available in 2019 and intend to immediately submit the data to the relevant regulatory agencies for market approval in Europe.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top